PRMT1作为MHC-I和抗瘤免疫的抑制剂
Tirta M Djajawi1, Lizzy Pijpers2, Akash Srivaths1
1Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC 3086, Australia.
Cell reports
|February 24, 2024
概括
蛋白质氨酸甲基转移酶1 (PRMT1) 通过抑制T细胞杀死来限制癌症免疫力. 抑制PRMT1可以提高免疫疗法的有效性,并为癌症患者提供新的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 癌症生物学 癌症生物学
背景情况:
- 癌症免疫疗法显示出希望,但面临的挑战是患者的反应和抵抗.
- 鉴定抗瘤免疫的表观遗传调节剂对于提高治疗疗效至关重要.
研究的目的:
- 通过CRISPR-Cas9查,识别限制CD8+T细胞介导抗瘤免疫力的表观遗传学因素.
- 研究PRMT1在调节抗瘤免疫反应中的作用及其作为治疗点的潜力.
主要方法:
- 针对表观遗传基因的CRISPR-Cas9选被用来识别关键调节者.
- 使用PRMT1淘汰和药理抑制 (GSK3368715) 来评估其功能.
- 分析了STAT1的表达和激活,以了解PRMT1作用的机制.
- 癌症基因组图谱 (TCGA) 数据库被用于人类黑色素瘤的相关分析.
主要成果:
- 确定PRMT1是干扰素 (Ifnγ) 诱导的MHC-I表达的抑制剂,从而影响CD8+T细胞的杀死.
- 通过增加STAT1信号传递,PRMT1抑制增强了Ifnγ诱导的MHC-I表达.
- 在临床前模型中,PRMT1的丧失改善了抗PD-1免疫疗法的疗效.
- TCGA分析显示,PRMT1表达和免疫标记 (MHC-I,CD8+ T细胞) 与黑色素瘤患者的存活率之间存在逆相关性.
结论:
- PRMT1通过调节MHC-I表达和T细胞介导的细胞毒性,作为抗瘤免疫的负调节剂.
- 针对PRMT1,特别是与GSK3368715等I型PRMT抑制剂的向,是增强癌症免疫治疗的有希望的策略.
- PRMT1抑制剂可以作为独立治疗或与现有的免疫疗法结合使用,以克服耐药性并改善患者的治疗结果.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
MicroRNAs
21.3K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.3K
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524


